The deal should give Invitrogen an opportunity to enter new markets in immunology, oncology and neurodegenerative disease, will strengthen its proteomics portfolio, and reinforce its research arm.
Invitrogen will take ownership of BioSource’s portfolio of protein and primary antibody products, as well as its kinase and cytokine analysis technologies for research applications.
“The acquisition of BioSource enables our company to continue its growth in the vital area of proteomics,” said Gregory Lucier, chairman and CEO of Invitrogen Corporation. “Moreover, the potential combination of BioSource’s strength in technology development and our leading brand positions us to achieve an important goal of developing a collection of disease specific tools.”
The transaction is subject to regulatory approval and the approval of BioSource stockholders, but is expected to close by the end of the year.